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Biphasic calcium phosphate ceramic granules (0.5–1.0mm) with a hydroxyapatite and β-tricalcium phosphate ratio of 90/10 were
used. Biphasic calcium phosphate ceramic granules produced in the Riga Technical University, Riga Rudolph Cimdins Bio-
materials Innovation and Development Centre, were used for filling the bone loss on 18 patients with peri-implantitis. After 5
years at the minimum, clinical and 3D cone-beam computed tomography control was done. Clinical situation confirmed good
stability of implants without any signs of inflammation around. Radiodensity of the previous gap and alveolar bone horizontally
from middle point of dental implants showed similar radiodensity as in normal alveolar bone. +is trial is registered
with ISRCTN13514478.
1. Introduction
Implant-based treatment is a growing part in the modern
dentistry. Loss of alveolar bone around dental implants is
revealed in 5–10% of patients. A dental implant is considered
to be a failure if it is lost, mobile, or shows peri-implant bone
loss of greater than 1.0mm in the first year and greater than
0.2mm a year after. Peri-implantitis can result in bone loss
around the implant and eventual loss of the implant [1].
Peri-implantitis is a site-specific infectious disease that
causes an inflammatory process in soft tissues and bone loss
around an osseointegrated implant in function [2].
+e etiology of the implant infection is conditioned by
the status of the tissue surrounding the implant, implant
design, degree of roughness, external morphology, and
excessive mechanical load.
Regenerative treatment of peri-implantitis also is
a growing problem. +e optimal result of peri-implantitis
treatment is the regeneration of hard and soft tissues sup-
porting the loose dental implant [3–6].
In the peri-implantitis treatment together with operative
and conservative treatment, bone substitutes are often used
to replace the bone defect; one of the materials is biphasic
calcium phosphate (BCP).
BCP is widely used to increase bone after tooth ex-
traction and in dental implantation, also in peri-implantitis
treatment.
Calcium phosphates, such as hydroxyapatite (HAp),
β-tricalcium phosphate (β-TCP), and a combination of
HAp/β-TCP, are used since they do not evoke adverse
cellular reactions and, in time, the material is either replaced
by bone or integrated into the body, depending on the
degradation properties [7–9].
HAp and β-TCP or their combination due to their
osteoconductivity, crystallographic structures, and chemical
composition similar to the skeletal tissue are widely used.
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+ey are classified according to their “resorbability,” that is
extent of degradation in vivo. HAp has been described as
“nonresorbable,” and β-TCP has been described as
“resorbable.”
BCP bioceramic materials have possibly double
action—stable increase of bone in volume and improvement
of the remineralization depending on HAp and β-TCP re-
lations. HAp strengthens and improves mineralization of the
natural bone, which is extremely necessary for good dental
implant integration. Radiological densitometric analysis can
prove it [3, 10].
+e aim of study is to analyze the results of peri-
implantitis treatment, where in addition to the classical
surgical technique, the bone defect around the dental im-
plant was filled with BCP bioceramic granules. Radiological
investigation using 3D cone-beam computed tomography
(3D CT) can objectivize the results.
2. Materials and Methods
+is clinical trial included 18 patients.+emain criterion for
selecting the patients for this study was the presence of peri-
implatitis at any stage, whereas the time of implant place-
ment and the appearance of the first symptoms of peri-
implantitis were not taken into account. +e age and sex of
the patient were not taken into account either.
An important criterion for the selection of the patients
was the surgery treatment with addition of BCP, which were
developed and produced by Riga Technical University
(RTU), Riga Rudolph Cimdins Biomaterials Innovation and
Development Centre.
Another important patient selection criterion in this
study was the presence of a 3D CT before and after treatment
of peri-implantitis. +e second, control, 3D CT was done at
least 5 years after the treatment.
For the peri-implantitis classification, Riga Institute of
Stomatology, Oral and maxillofacial surgery department
uses two classifications: Froum and Rosen classification of
peri-implantitis [11] and Ata-Ali classification of peri-
implantitis [12].
+ese classifications allow to assess the degree of peri-
implantitis, choose treatment tactics, as well as evaluate the
quality of treatment.
2.1. Peri-Implantitis Treatment. Our patients underwent
treatment by the following surgical protocol, which is a re-
liable and predictable solution in the treatment of pro-
gressive peri-implantitis:
(i) Systemic antibiotics 3 times/day for 2 days before
surgery
(ii) Preoperative rinse for 1 minute with a 0.2%
chlorhexidine solution
(iii) Local anaesthesia with articaine solution
(iv) Design of mucoperiosteal flap
(v) Determining the size of the infected area
(vi) Mechanical cleaning, curettage of the implant surface
(vii) +e application of a gauze pad moistened with
a 2% chlorhexidine solution in the area of bone
defect for 5 minutes
(viii) After removing the gauze swab, the defect is
washed by 1 g of tetracycline dissolved in 20ml of
sterile physiological solution
(ix) +e bone defect filling with bioactive materi-
al—HAp/β-TCP
(x) +e wound closure with a surgical suture
(xi) Systemic antibiotics 3 times/day for 3 days after
surgery
+e choice of an antibacterial drug depended on the
patient. +e first choice of the prescribed drug was
Amoxicillin 500mg; in case of allergies to this drug, Clin-
damycin 150mg was chosen (Figure 1).
2.2. Source of Implantable Materials. Calcium-deficient
hydroxyapatite (CDHAp) was synthesized by an aque-
ous precipitation technique, where calcium hydroxide and
phosphoric acid were used as raw materials in the reaction
as follows: Ca(OH)2 + H3PO4/Ca10 − x(HPO4)x(PO4)6 −
x(OH)2 − x + H2O. +e filtered precipitates were formed
into granules, dried, and sintered at 1150°C for 2 h. During
the sintering process, CDHAp transformed into BCP ce-
ramics with the HAp/β-TCP ratio of 90/10. Sintered granules
between 0.5 and 1mmwere obtained using vibrational sieves,
and the sieved granules were washed in ethanol and dried in
a drying oven at 105°C for 24 h. Prior to application, the dried
granules were sterilized using steam sterilization.
SEM images revealed the irregular shape and micro-
structure of BCP granules.+emicrostructure is composed of
relatively dense structure with grain size d < 1 µm and
nanosized pores confirming gas adsorption results (Figure 2).
Nanopores could be critical for flow of body fluids and
protein adsorption [13].
2.3. 3D Cone-Beam Computed Tomography. +e inclusion
criterion was the presence of the full series of qualitative 3D
CT scans at two time points—one preoperative and one
postoperative at least five years after treatment. Modern 3D
CT allows obtain images of high quality, while patients are
not at risk of high radiation doses [14]. +e purpose of
second imaging was to monitor the precision and quality of
surgery. 3D CT was done with i-CAT Next Generation
(KAVO, Germany). Image volume was reconstructed with
0.3mm voxel size. +e tube voltage was 120 kVp, tube
current was 5mA, and exposure time 20 seconds. For image
reconstruction, ExamVision program was used (Figure 3).
Densitometry was carried out in 8 points—the first point
is the dental implant centre, this is the standard beginning
point for all measurements, then 2 points with 2mm step in
mesial and distal direction, as well as 2 points with 2mm step
in buccal and lingual direction. +e first point is 2mm from
implant surface, and the second point is 2mm more from
previous measurement point (Figure 4).
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3. Results
Patients at least 5 years follow-up show good clinical results,
which are further confirmed by 3D CT.
To simplify the assessment of the quality of the
treatment using the costuming agent based on calcium
hydroxyapatite, the percentage of bone tissue loss (the
depth of the bone pocket) was taken with respect to the
body of the dental implant before and after therapy. In
average, bone pocket depth was 34.6% ± 5.4% of the dental
implant length and it decreased to 22.3% ± 3.4% after
regenerative surgery.
In conformity with Froum classification of peri-
implantitis before the treatment, the second stage was
revealed in three cases and the third stage in 15 cases. After
treatment, the first stage was in 10 cases and the second stage
in 8 cases. In conformity of Ata-Ali classification of peri-
implantitis the second stage was in one case, the third stage
in 3 cases, and the fourth stage in 14 cases, and after
treatment, the first stage was in 7 cases and the second stage
in 11 cases (Table 1).
Another method to prove the quality of treatment is
measurement of bone densitometry. +e results of densi-
tometry indicate an improvement in the mineralization of
bone tissue quality (Tables 2 and 3).
+ese parameters are quite stable, as evidenced by Pear-
son’s correlation coefficients.
Pearson’s correlation coefficients were calculated between
the variables as follows: mediodistally point 1 (mes 1) and
mediodistally point 2 (mes 2), mediodistally point 3 (mes 3) and
mediodistally point 4 (mes 4), linguobuccally point 1 (ling 1)
and linguobuccally point 2 (ling 2), as well as linguobuccally
Figure 1: Surgery procedure. (a) Design of mucoperiosteal flap, determining the size of the infected area. (b) Mechanical cleaning, curettage
of the implant surface. (c) Insertion of implants composed of HAp/β-TCP (ratio of 90/10). (d) Closed wound.
2 mm 10 µm 2 µm
Figure 2: SEM microphotographies of BCP ceramic granules.
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point 3 (ling 3) and linguobuccaly point 4 (ling 4).+e following
correlations and p values were obtained:
Cor (mes 1, mes 2) � 0.781 (p< 0.001)
Cor (mes 3, mes 4) � 0.443 (p � 0.065)
Cor (ling 1, ling 2) � 0.785 (p< 0.001)
Cor (ling 3, ling 4) � 0.582 (p � 0.011)
In all cases, there is a positive relationship (Figures 5–8).
At the significance level α � 0.05, the Pearson’s correlation
coefficients between the variables mes 1 andmes 2, ling 1 and
ling 2, as well as ling 3 and ling 4 are statistically significant.
+e only thing that was not statistically significant is
Pearson’s correlation coefficient between the variables mes 3
and mes 4.
Figure 3: 3D CT scans of dental implants. Measuring points for densitometry (green).
Figure 4: Points of measurement of mineral density (HU).
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4. Discussion
Treatment methods of peri-implantitis are different, and
results of investigations and recommendations are con-
tradictory. In general, in the current situation, the surgical
therapy with resective and augmentative procedures
completes the treatment options. Surgery can be used in
order to eliminate peri-implantitis defects, to re-establish
hygienic abilities, and to reduce or even stop peri-
implantitis progression whereas regenerative therapies
may be applicable for defect filling [15, 16]. Not in all
studies a benefit for these treatments compared to de-
bridement alone was obtained [17].
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Figure 5: Vertical loss of alveolar bone around dental implants
before. Variables mes 1 versus mes 2.
Table 2: Alveolar bone densitometry (HU) mediodistally (4
points).
Case no. 1st point 2nd point 3rd point 4th point
1 646.8 422.6 388 632.3
2 652.7 430.7 406.4 648.6
3 640.3 424.2 418.1 635.2
4 642.4 426.8 392.2 637.4
5 656.8 430.2 432.8 650.1
6 653.7 424.8 418.3 649.2
7 644 425.6 412.3 642.2
8 650.3 423.8 424.3 648.6
9 649.7 428.2 418.8 652.2
10 648.2 424.4 430.4 642.8
11 642.5 420.6 424.3 640.6
12 636.4 418.1 398.4 642.2
13 640.8 418.1 422.2 636.4
14 642.3 423.2 415.1 638.2
15 628.3 402.1 404.2 620.8
16 643.1 422.3 409.5 638.8
17 643.6 412.6 409.4 641.7
18 632.2 418.2 412.4 629.2
Table 3: Alveolar bone densitometry (HU) linguobuccally (4
points).
Case no. 1st point 2nd point 3rd point 4th point
1 665.6 422 420.3 666
2 648.3 428.4 418.2 652.8
3 652.3 430.7 426.3 640.3
4 636.4 418 404.8 625.2
5 648.9 422.2 428.2 652.5
6 642.2 412.2 406.5 637.6
7 631.2 406.2 410.6 632.2
8 642.4 418.2 424.8 638.2
9 652.2 426.1 416.2 640.3
10 640.3 424.4 426.6 648.6
11 636.2 412.2 418.2 641.8
12 626.2 398.2 390.8 632.4
13 632.4 402.2 412.6 626.2
14 640.2 422.8 428.8 642.3
15 632.8 410.3 412.7 628.6
16 628.3 399.8 389.4 616.9
17 626.9 402.8 399.8 630.6
18 618.8 409.6 418.8 616.8
Journal of Healthcare Engineering 5
We are on the regenerative approach and use BCP
materials for replacement of bone defect. +e main com-
ponent HAp was initially considered as bioinert bio-
material till the time when the osteoinductive property was
confirmed by Ripamonti [18] and Zhang et al. [19]. Later
bioactivity of BCP materials was confirmed [20]. Also
regenerative potency of BCP activation of endogenous
growth factor TGFβ after implantation in experiment was
obtained [21, 22]. Activation of endogenous osteoprote-
gerin turns on bone remodelling from osteoclastogenesis to
osteoblastogenesis is a positive action of BCP biomaterials
in use for recovery of bone defects [23]. Peri-implantitis
bone defects, treated in regenerative way in experiments,
can be filled by hybrid of living bone and inorganic, but
bioactive biomaterial [24]. Our long-term results con-
firmed effectiveness of synthetic BCP bioceramic materials
in regenerative treatment of peri-implantitis.
+e unique phase composition and porous structural
features of osteoinductive Ca-P ceramics allow to interact
with signalling molecules and extracellular matrices in the
host system, creating a local environment conductive to new
bone formation [25].
+e use of 3D CTgives a good, noninvasive approach for
determining the depth of peri-implantitis defect and healing
of it after therapy. We used 3D CT imaging to confirm the
defect after clinical evaluation of the patient and give
a glance of it extent.
5. Conclusion
Comparing the indices of radiological measurement of the
depth of the osseous pockets, radio densitometry of the bone
structures before and after treatment of peri-implantitis with
the use of pure calcium hydroxyapatite, it may be concluded
that long-term results after 5 years are stable. +e radio-
density of bone tissue after the application of synthetic
biomaterial based on calcium hydroxyapatite differs a little
from the intact bone of the patient, which may indicate
a high degree of mineralization after implantation of calcium
hydroxyapatite crystals.
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C. H. Hammächer, and J. M. Stein, “Definition, etiology,
prevention and treatment of peri-implantitis–a review,” Head
and Face Medicine, vol. 10, no. 1, pp. 34–38, 2014.
[16] M. Aljateeli, J. H. Fu, and H. L. Wang, “Managing peri-implant
bone loss: current understanding,” Clinical Implant Dentistry
and Related Research, vol. 14, no. S1, pp. e109–e118, 2012.
[17] F. Schwarz, N. Sahm, K. Bieling, and J. Becker, “Surgical
regenerative treatment of peri-implantitis lesions using
a nanocrystalline hydroxyapatite or a natural bone mineral in
combination with a collagen membrane: a four-year clinical
follow-up report,” Journal of Clinical Periodontology, vol. 36,
no. 9, pp. 807–814, 2009.
[18] U. Ripamonti, “Bone induction in nonhuman primates: an
experimental study on the baboon,” Clinical Orthopaedics and
Related Research, vol. 269, pp. 284–294, 1991.
[19] X. Zhang, P. Zou, C. Wu et al., A Study of Porous Block HA
Ceramics and Its Osteogenesis. Bioceramics and the Human
Body, Elsevier, Amsterdam, Netherlands, 1991.
[20] U. Ripamonti, P. W. Richter, R.W. Nilen, and L. Renton, “+e
induction of bone formation by smart biphasic hydroxyap-
atite tricalcium phosphate biomimetic matrices in the non-
human primate Papio ursinus,” Journal of Cellular and Mo-
lecular Medicine, vol. 12, no. 6b, pp. 2609–2621, 2008.
[21] I. Salma, M. Pilmane, A. Skagers et al., “Early morphofunc-
tional response of contact tissue after intraosal implantation
in rabbit jaw of pure synthetic hydroxyapatite (HAp) bio-
ceramic materials and HAp saturated with lidocaine,”
Stomatologij-Baltic Dent Maxillofac Journal, vol. 11, no. 4,
pp. 113–118, 2009.
[22] I. Salma, M. Pilmane, J. Vetra, L. Berzina-Cimdina, G. Salms,
and A. Skagers, “Expression of transforming growth factorβ
(TGFβ) in rabbit jaw after intraosaly implanted synthetic
(HA) ceramic materials,” Turku Scandbalt Biomaterials Days
26–28 September, p. 24, 2007.
[23] S. Petronis, M. Pilmane, J. Locs, and A. Skagers, “OPG/
RANKL signaling pathway in osteoporotic bone can be tar-
geted by biphasic calcium phosphate bioceramics,” European
Cells and Materials, 8th Annual Meeting of the Scandinavian
Society for Biomaterials, vol. 29, no. S1, p. 55, 2015.
[24] S. Kim, U. W. Jung, Y. K. Lee, and S. H. Choi, “Effects of
biphasic calcium phosphate bone substitute on circumfer-
ential bone defects around dental implants in dogs,” In-
ternational Journal of Oral andMaxillofacial Implants, vol. 26,
no. 2, pp. 265–273, 2011.
[25] Z. Tang, X. Li, Y. Tan, H. Fan, and X. Zhang, “+ematerial and
biological characteristics of osteoinductive calcium phosphate
ceramics,” Regenerative Biomaterials, vol. 5, no. 1, pp. 43–59,
2018.

















































































 Advances in 
Multimedia
Submit your manuscripts at
www.hindawi.com
